Leuven, Belgium, Boston, MA, US - May 6,2022 - 07.00 PM CET -Oxurion NV(Euronext Brussels: OXUR) (the "Company" or "Oxurion"), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, held its extraordinary and annual shareholders' meetings on May 3, 2022. The shareholders approved all items on the agenda of the annual shareholders' meeting. Concerning the extraordinary shareholders' meeting, the attendance quorum required to deliberate and vote on the agenda items was not met, therefore, no deliberation or vote was held.
All documents pertaining to the extraordinary and annual shareholders' meeting held on May 3, 2022, can be consulted on Oxurion's website Oxurion/shareholders.
Considering the foregoing, Oxurion announces and convenes a second extraordinary shareholders' meeting that will be held on Tuesday, May 24, 2022, at 10:00 AM.
About Oxurion
Oxurion.
Important information about forward-looking statements
Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.
For further information please contact:
| Oxurion NV Tom Graney Chief Executive Officer Tel: +32 16 75 13 10 tom.graney@oxurion.com (mailto:tom.graney@oxurion.com) Michaël Dillen Chief Business Officer Tel: +32 479 783 583 michael.dillen@oxurion.com (mailto:michael.dillen@oxurion.com) | US Conway Communications Beth Kurth bkurth@conwaycommsir.com (mailto:bkurth@conwaycommsir.com) ICR Westwicke Christopher Brinzey Tel: +1 617 835 9304 chris.brinzey@westwicke.com (mailto:chris.brinzey@westwicke.com) |
Attachment
- PR Oxurion NV_Results AGM-EGM-Convocation EGM_(ENG)_20220506_FINAL (https://ml-eu.globenewswire.com/Resource/Download/54c0bb8e-7b88-417e-a622-fdbc71e6018c)
